Surrozen, Inc.: financial analysis
Ratios worked out from 7 fiscal years of Surrozen, Inc.'s statements, compared with 670 companies in Biotechnology.
Surrozen, Inc. scorecard#
Passes 1 of the 14 checks that could be worked out: strongest in financial health (1 of 3), weakest in valuation (0 of 5). Fiscal year 2025; market cap of Oct 30, 2026.
Valuation0 of 5
- ✗P/E below its peers' medianNo P/EThe company made a loss over the last twelve months.
- ✗Price to book below its peers' medianNo price to bookShareholders' equity is negative.
- ✗Price to sales below its peers' median161.4×Price to sales 161.4× against Biotechnology's median of 8.6×.
- ✗Free cash flow yield above 5%-5.4%Free cash flow is -5.4% of the market value.
- ✗Earnings yield above the 10-year Treasury yieldLossA loss earns nothing against the 10-year Treasury's 4.92% (2026-11-20).
- –The price assumes slower growth than the last three years'Free cash flow of the last three years is missing or below zero on average.
Growth0 of 3
- ✗Revenue grew in the newest year-67.3%Revenue down 67.3% in fiscal 2025.
- –Revenue up more than 5% a year over three yearsRevenue of three years earlier is not on file.
- –Faster growth over three years than its peers' medianRevenue of three years earlier is not on file.
- ✗Earnings per share grew in the newest year-32.37 vs -21.67Diluted EPS -32.37 in fiscal 2025 against -21.67 the year before (report's currency).
- ✗Net income higher than five years earlier-$242 M-$242 M in fiscal 2025 against -$33 M in 2020.
- –Revenue rose in at least four of the last five yearsFive years of revenue changes are not on file.
Profitability0 of 2
- ✗Profitable in the newest year-$242 MNet income -$242 M in fiscal 2025.
- ✗Profitable in each of the last five years0 of 5Profitable in 0 of the five years to fiscal 2025.
- –Operating margin above its peers' medianNo operating margin on file.
- –Return on equity above 15%No return on equity (equity missing or negative).
- –Return on invested capital above 10%No return on invested capital on file.
- –Operating margin wider than three years earlierOperating margins of three years earlier are not on file.
Financial health1 of 3
- ✓Short-term assets cover short-term liabilities9.2×Current ratio 9.22 at the end of fiscal 2025.
- –Debt below equityDebt or equity is not on file (or equity is negative).
- –Net debt below three years of EBITDANet debt to EBITDA is not on file.
- –Operating income covers interest five timesInterest expense is not on file.
- ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2025.
- ✗Altman Z-score outside the distress zone-6.68Z-score -6.68 (distress zone) for fiscal 2025.
Shareholder returns0 of 1
- –Pays a dividendDividends are not on file.
- –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
- –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
- ✗Share count up no more than 2% in a year133.3%Diluted shares up 133.3% in fiscal 2025.
- –Dividends and buybacks above 3% of the market valueDividends and buybacks are not on file.
- –Free cash flow covers dividends and buybacksPaid out nothing in the newest year.
Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 20, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work
What the 2025 statements show#
Each line is an observation with its numbers, not a judgement of the company.
Worth a look
- Revenue fell 67.3% against the year before.
- Net loss of $242 million, the 6th loss-making year in a row.
- Free cash flow was negative: -$30 million.
- The share count rose 133.3% in the year.
- Shareholders' equity is negative: -$188 million.
Piotroski F-score
Nine yes/no tests of whether the company's finances improved in the year. One point each.
- Made a profitno
- Operations brought in cashno
- Return on assets roseno
- Cash from operations exceeds profityes
- Long-term debt fell against assetsnot on file
- Current ratio roseyes
- No new shares issuedno
- Gross margin rosenot on file
- Asset turnover roseno
Altman Z-score
A 1968 formula that weighs five balance-sheet ratios. It was built on listed manufacturers and says less about other kinds of company.
| Part | Ratio | Weight | Points |
|---|---|---|---|
| Working capital to assets | 0.83 | × 1.2 | 0.99 |
| Retained earnings to assets | -5.34 | × 1.4 | -7.48 |
| Operating income to assets | -0.43 | × 3.3 | -1.41 |
| Market value to liabilities | 1.96 | × 0.6 | 1.18 |
| Revenue to assets | 0.04 | × 1 | 0.04 |
Profitability#
| Fiscal year | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | Median of peers | Ahead of |
|---|---|---|---|---|---|---|---|---|
| Operating margin | — | -239.6% | — | -354.7% | — | -60.5% | — | |
| Net margin | — | -596.3% | — | -288.0% | — | -68.9% | — | |
| Return on equity | — | — | -75.6% | -38.8% | -69.6% | -61.0% | — | |
| Return on assets | -328.9% | -134.5% | -63.5% | -31.8% | -54.9% | -44.4% | 3% |
Growth#
| Fiscal year | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | Median of peers | Ahead of |
|---|---|---|---|---|---|---|---|---|
| Revenue growth | -67.4% | — | — | — | — | 15.8% | 5% |
Financial strength#
| Fiscal year | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | Median of peers | Ahead of |
|---|---|---|---|---|---|---|---|---|
| Current ratio | 9.22× | 5.32× | 5.75× | 8.36× | 7.75× | 4.39× | 76% | |
| Equity share of assets | -190.2% | -44.1% | 82.3% | 85.0% | 80.0% | 64.3% | 4% |
Cash#
| Fiscal year | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | Median of peers | Ahead of |
|---|---|---|---|---|---|---|---|---|
| Free cash flow | $-30 M | $-18 M | $-41 M | $-45 M | $-50 M | $-40 M | 54% | |
| Free cash flow margin | -872.7% | -165.7% | — | -359.0% | — | -61.5% | 2% | |
| Capital spending share of revenue | 3.7% | 0.3% | — | 5.8% | — | 1.7% | — |
Efficiency#
| Fiscal year | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | Median of peers | Ahead of |
|---|---|---|---|---|---|---|---|---|
| Asset turnover | 0.05× | 0.23× | — | 0.11× | — | 0.26× | 16% |
How each figure is worked out#
- Operating margin
- Operating income as a share of revenue.
- Net margin
- Net income as a share of revenue.
- Return on equity
- Net income as a share of shareholders' equity (the average of the start and the end of the year). Not given when equity is negative.
- Return on assets
- Net income as a share of total assets (average of the year).
- Revenue growth
- Revenue against the year before.
- Current ratio
- Assets due within a year divided by liabilities due within a year.
- Equity share of assets
- Shareholders' equity as a share of total assets.
- Free cash flow
- Cash from operations less capital spending.
- Free cash flow margin
- Free cash flow as a share of revenue.
- Capital spending share of revenue
- Capital spending as a share of revenue.
- Change in share count
- Diluted shares against the year before. Negative: fewer shares.
- Asset turnover
- Revenue divided by total assets (average of the year).